LUNG Nov 2024 5.000 call
| Previous close | 2.6500 |
| Open | 2.6500 |
| Bid | 1.3500 |
| Ask | 2.1500 |
| Strike | 5.00 |
| Expiry date | 2024-11-15 |
| Day's range | 2.6500 - 2.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
ZacksHow Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GlobeNewswirePulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the “Compensation Committee”) granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock on Ma
ZacksWall Street Analysts See a 56.11% Upside in Pulmonx (LUNG): Can the Stock Really Move This High?
The consensus price target hints at a 56.1% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
